SR One Capital Management Discloses 7.5% Stake in Avalyn Pharma Post-IPO
Summary
SR One Capital Management and its affiliates, including Simeon George, disclosed a 7.5% beneficial ownership stake in Avalyn Pharma Inc. following the company's initial public offering, acquired through preferred stock conversion and IPO participation.
Key Events
-
Significant Institutional Ownership Disclosed
SR One Capital Management and its affiliates, including Simeon George, reported a 7.5% beneficial ownership stake in Avalyn Pharma Inc.
-
Post-IPO Stake Establishment
The 3,308,649 shares were acquired through the conversion of preferred stock and participation in the recent IPO at $18.00 per share, formalizing a major investor's position after the company's public debut.
-
Lock-up and Registration Rights
The reporting persons are subject to a 180-day lock-up period post-IPO, preventing immediate sales, but also hold customary registration rights for future share dispositions.
Analysis
This Schedule 13D filing formalizes the significant ownership position of SR One Capital Management, a venture capital firm, and its managing member, Simeon George, in Avalyn Pharma Inc. post-IPO. The stake, totaling 3,308,649 shares, represents 7.5% of the company's common stock. The shares were acquired through a combination of preferred stock conversion and participation in the recent IPO at $18.00 per share. While the filing indicates the shares are held for investment purposes, it also highlights a 180-day lock-up agreement preventing immediate sales and outlines future registration rights, providing a pathway for potential liquidity. This disclosure confirms substantial institutional backing for Avalyn Pharma following its public debut.
At the time of this filing, AVLN was trading at $27.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $25.05 to $30.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.